Avatar of Somesh

Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) Market Report -Pipeline Review, H2 2017

0 rating, 0 votes0 rating, 0 votes (0 rating, 0 votes, rated)
You need to be a registered member to rate this post.
Loading ... Loading ...

October 9, 2017 in Economics

by

“The Latest Research Report Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15)-Pipeline Review, H2 2017 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. – MarketResearchReports.biz”

About Cathepsin L1 Market

According to the recently published report ‘Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15)-Pipeline Review, H2 2017′; Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) pipeline Target constitutes close to 5 molecules. Out of which approximately 5 molecules are developed by Companies.

Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15)-Cathepsin L, a lysosomal endopeptidase is a member of the papain-like family of cysteine proteinases. Cathepsin L plays a major role in antigen processing, tumor invasion and metastasis, bone resorption, and turnover of intracellular and secreted proteins involved in growth regulation. Although commonly recognized as a lysosomal protease, cathepsin L is also secreted. The cathepsin L gene is activated by a variety of growth factors, tumor promoters, and second messengers. Cathepsin L promote tumor cell invasion and metastasis by catalyzing degradation of the interstitial matrix and basement membranes, thus allowing cancer cells to invade locally and metastasize to distant sites.

Get Sample copy of this Report @ https://www.marketresearchreports.biz/sample/sample/1339575

The report ‘Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15)-Pipeline Review, H2 2017′ outlays comprehensive information on the Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase 0, Preclinical and Discovery stages are 1, 3 and 1 respectively. Report covers products from therapy areas Oncology, Central Nervous System, Gastrointestinal, Immunology and Infectious Disease which include indications Autoimmune Disorders, Breast Cancer, Cancer Pain, Head And Neck Cancer Squamous Cell Carcinoma, Liver Fibrosis, Metastatic Prostate Cancer, Middle East Respiratory Syndrome (MERS), Neuropathic Pain, Pancreatic Cancer, Primary Biliary Cirrhosis and Severe Acute Respiratory Syndrome (SARS).

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

View Sample PDF @ https://www.marketresearchreports.biz/reports/1339575/cathepsin-l1-cathepsin-l-or-major-excreted-protein-or-ctsl-or-ec-342215-pipeline-review-h2-2017-market-research-reports.pdf

Scope

- The report provides a snapshot of the global therapeutic landscape for Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15)

- The report reviews Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) targeted therapeutics and enlists all their major and minor projects

- The report assesses Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Send An Enquiry Request @ https://www.marketresearchreports.biz/sample/enquiry/1339575

Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 3

Introduction 4

Global Markets Direct Report Coverage 4

Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15)-Overview 5

Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15)-Therapeutics Development 6

Products under Development by Stage of Development 6

Products under Development by Therapy Area 7

Products under Development by Indication 8

Products under Development by Companies 9

Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15)-Therapeutics Assessment 11

Assessment by Mechanism of Action 11

Assessment by Route of Administration 12

Assessment by Molecule Type 13

Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15)-Companies Involved in Therapeutics Development 14

Mateon Therapeutics Inc 14

Phelix Therapeutics LLC 14

Virobay Inc 14

Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15)-Drug Profiles 16

Drugs to Inhibit Cathepsin L for Coronaviridae Infections-Drug Profile 16

Product Description 16

Mechanism Of Action 16

R&D Progress 16

KGP-420-Drug Profile 17

Product Description 17

Mechanism Of Action 17

R&D Progress 17

KGP-94-Drug Profile 18

Product Description 18

Mechanism Of Action 18

R&D Progress 18

VBY-285-Drug Profile 19

Product Description 19

Mechanism Of Action 19

R&D Progress 19

VBY-825-Drug Profile 20

Product Description 20

Mechanism Of Action 20

R&D Progress 20

Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15)-Dormant Products 21

Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15)-Product Development Milestones 22

Featured News & Press Releases 22

Mar 31, 2017: Mateon Therapeutics Announces Abstract Presentations for the American Association for Cancer Research Annual Meeting in April 2017 22

Apr 07, 2014: OXiGENE Announces Results of KGP94 Preclinical Studies at 2014 AACR Conference 22

Mar 27, 2014: OXiGENE Announces Presentation of Preclinical Abstracts at 2014 AACR Conference 23

Nov 14, 2011: Virobay’s Spectrum-Selective Cathepsin Inhibitor Shows Efficacy In Bone Cancer Model 23

Appendix 25

Methodology 25

Coverage 25

Secondary Research 25

Primary Research 25

Expert Panel Validation 25

Contact Us 25

Disclaimer 26

About us

MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Contact

Mr. Nachiket

State Tower

90 Sate Street, Suite 700

Albany, NY 12207

Tel: +1-518-621-2074

Website: http://www.marketresearchreports.biz/

E: sales@marketresearchreports.biz

Infowars.com Videos:

Comment on this article:

Leave a reply

You must be logged in to post a comment.